AbbVie (NYSE:ABBV) Issues Quarterly Earnings Results

AbbVie (NYSE:ABBV) issued its earnings results on Wednesday. The company reported $2.65 earnings per share for the quarter, missing the consensus estimate of $3.01 by ($0.36), FiscalAI reports. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 earnings per share.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie beat Q1 expectations with adjusted EPS of $2.65 and $15 billion in revenues, and raised full‑year adjusted EPS guidance by $0.12 to $14.08–$14.28, citing stronger-than-expected demand across the portfolio.
• Immunology momentum remains a key driver—SKYRIZI sales were $4.5B (up ~29% operationally) and management now models ~$21.6B for 2026, while RINVOQ reached $2.1B (up ~20%) with a $10.2B full‑year assumption, both outperforming expectations.
• Pipeline progress in gastroenterology was highlighted—subcutaneous induction SKYRIZI for Crohn’s was submitted in the U.S. with an approval decision expected later this year, and a combo of SKYRIZI + ABBV‑382 showed ~42% endoscopic remission at week 24 in a highly refractory cohort, suggesting potentially transformational efficacy.
• Early-stage R&D catalysts include encouraging obesity data for the long‑acting amylin analog ABBV‑295 (~10% weight loss in 12 weeks, good tolerability) and an accelerated oncology plan with etentamig now expected to be submitted by year‑end, both cited as near‑term growth opportunities.
• The FDA issued a complete response letter for TrenibotE due to manufacturing questions (no safety/efficacy issues), delaying a U.S. approval path while international launches are still expected later this year.

AbbVie Stock Up 3.3%

ABBV stock opened at $204.20 on Thursday. The company has a 50-day simple moving average of $214.80 and a 200 day simple moving average of $221.67. The company has a market capitalization of $361.06 billion, a P/E ratio of 86.53, a PEG ratio of 0.71 and a beta of 0.38. AbbVie has a fifty-two week low of $176.57 and a fifty-two week high of $244.81.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.4%. AbbVie’s dividend payout ratio is presently 293.22%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler reduced their target price on shares of AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. UBS Group decreased their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Finally, Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $252.38.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AbbVie

A number of institutional investors have recently added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC lifted its holdings in shares of AbbVie by 56.3% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. IFC & Insurance Marketing Inc. bought a new position in AbbVie during the fourth quarter valued at about $31,000. Quarry LP acquired a new position in AbbVie during the third quarter worth about $41,000. Finally, Jessup Wealth Management Inc acquired a new position in AbbVie during the fourth quarter worth about $42,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 results: Revenue of $15.00B beat consensus and AbbVie raised 2026 adjusted EPS guidance to $14.08–$14.28, citing Skyrizi/Rinvoq strength. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Bank of America upgraded ABBV from Neutral to Buy and set a $234 price target, supporting upside vs. current levels.
• Positive Sentiment: Regulatory progress: AbbVie submitted FDA applications/label-expansion filings for Rinvoq (upadacitinib) in alopecia areata and other indications — potential sales tailwind if approved. AbbVie Submits Application to FDA for Upadacitinib
• Positive Sentiment: Pipeline/BD: AbbVie holds an option/warrant around Kestrel (KRAS program) that could lead to up to $1.45B in deal value and expands oncology exposure. AbbVie sinks talons into KRAS with right to buy Kestrel
• Positive Sentiment: Partner milestone: EvolveImmune nomination triggered an $18M milestone payment tied to its AbbVie collaboration — near‑term non‑core cash positive. EvolveImmune Therapeutics Announces Achievement
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) launched a May philanthropic campaign via Allē — positive PR but limited direct financial impact. Allergan Aesthetics Launches Philanthropic Effort
• Neutral Sentiment: Valuation commentary: Several analyst pieces are re‑assessing AbbVie after recent price weakness; useful for longer‑term investors but not an immediate catalyst. Assessing AbbVie Valuation
• Negative Sentiment: Analyst revisions: Erste Group trimmed FY2026/FY2027 EPS estimates modestly (small downward revisions) — a warning that some sell‑side forecasts are being re‑tuned.
• Negative Sentiment: Legacy declines: Humira and Imbruvica continue to contract; though newer immunology and neuroscience products offset much of the decline, legacy erosion remains a structural headwind. AbbVie tops quarterly expectations

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.